arrow
M

Marijke Kamsteeg

radboudumc university medical center
H指数:27
被引数:2,774

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

International Multi-Center Case Series of Gestational Dupilumab Exposure in the Treatment of Atopic Dermatitis: Maternal Complications and Fetal Outcomes

国际多中心病例系列研究:妊娠期Dupilumab暴露于特应性皮炎治疗中的母体并发症和胎儿结局

2025-10-290
PRE
Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry

乌帕替尼在青少年难治性特应性皮炎日常实践中的应用:BioDay登记研究病例系列

2025-07-300
OA
Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results

特应性皮炎患者使用生物制剂和JAK抑制剂治疗时的感染风险:BioDay研究数据

2025-04-030
OAAI
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
2024-12-140
PRE
Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis
2024-10-012
PRE
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry
2024-08-015
OAAI
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry
2023-05-1312
OA
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry

Dupilumab在儿童特应性皮炎治疗中的日常实践: 来自BioDay注册表的28周临床和生物标志物结果

2022-12-0514
OA
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis Long-term Results From the Daily Practice BioDay Registry
2022-09-0123
OA
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry
2021-04-0158
OAAI
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry
2020-05-0537
OAAI
Targeting the Cutaneous Microbiota in Atopic Dermatitis by Coal Tar via AHR-Dependent Induction of Antimicrobial Peptides

煤焦油通过AHR依赖性诱导抗菌肽靶向特应性皮炎中的皮肤微生物群

2020-02-0166
OAAI
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry
2019-10-31110
OAAI